Table 1.
Patient characteristics
| Characteristics | n | Values |
|---|---|---|
| Age [yr] | 910 | 41.7 ± 11.7 |
| Females | 910 | 658 (72.3%) |
| Diabetic father | 860 | 198 (23.0%) |
| Diabetic mother | 881 | 277 (31.4%) |
| Obese father | 870 | 312 (35.9%) |
| Obese mother | 889 | 451 (50.7%) |
| Body mass index [kg/m2] | 910 | 46.7 ± 8.7 |
| Waist circumference [cm] | 891 | 130.3 ± 17.7 |
| Systolic blood pressure [mmHg] | 908 | 135.9 ± 18.6 |
| Diastolic blood pressure [mmHg] | 908 | 76.3 ± 14.2 |
| Diabetes | 910 | 350 (38.5%) |
| Patients on antidiabetic drugs | 892 | 281 (31.5%) |
| Patients with number of antidiabetic drugs | 892 | |
| 0 | 611 (68.5%) | |
| 1 | 126 (14.1%) | |
| 2 | 68 (7.6%) | |
| > 2 | 87 (9.8%) | |
| Patients on insulin treatment | 910 | 89 (9.8%) |
| Fasting blood glucose [mmol/L] | 898 | 5.6 (5.1 to 6.8) |
| Fasting plasma insulin [mUI/L] | 897 | 14.1 (9.3 to 21.1) |
| Fasting plasma C-peptide [ng/mL] | 701 | 3.8 (3.0 to 4.9) |
| 2 h blood glucose [mmol/L] | 868 | 7.5 (6.0 to 11.2) |
| 2 h plasma insulin [mUI/L] | 866 | 57.3 (30.1 to 102.3) |
| 2 h plasma C-peptide [ng/mL] | 618 | 10.5 (7.5 to 13.1) |
| HbA1c [%] | 902 | 5.9 (5.5 to 6.6) |
| HOMA2-B | 896 | 116.7 (82.4 to 162.8) |
| HOMA2-IR | 896 | 2.2 (1.4 to 3.2) |
| Hypertension | 910 | 727 (79.9%) |
| Patients on anti-hypertensive drugs | 910 | 386 (42.4%) |
| Total cholesterol [mmol/L] | 903 | 4.9 ± 1.0 |
| LDL cholesterol [mmol/L] | 896 | 3.0 ± 0.8 |
| HDL cholesterol [mmol/L] | 903 | 1.1 ± 0.3 |
| Triglycerides [mmol/L] | 903 | 1.7 ± 1.4 |
| Dyslipidemia | 910 | 904 (99.3%) |
| Patients on antidyslipidemia drugs | 910 | 217 (23.8) |
| Patients on statins | 910 | 173 (19.0) |
Key anthropometric and metabolic parameters, medications and comorbidities of obese patients prior to surgery (n = number of patients with available data for the indicated parameter) are shown. Values are presented as numbers and percentage, mean ± SD or median (IQR) as appropriate. Abbreviations: HbA1c hemoglobin A1c, HOMA2-B homeostasis model assessment of β-cell function, HOMA2-IR homeostasis model assessment of insulin resistance, LDL low density lipoprotein, HDL high density lipoprotein, IQR interquartile range, SD standard deviation